These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Influence of CD4+/CD25+ regulatory T cells on atherogenesis in patients with end-stage kidney disease. Meier P; Meier R; Blanc E Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):987-97. PubMed ID: 18666849 [TBL] [Abstract][Full Text] [Related]
24. The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II. Armani A; Becker RC Am Heart J; 2005 Jun; 149(6):977-83. PubMed ID: 15976778 [No Abstract] [Full Text] [Related]
25. Inflammatory disorders and atherosclerosis: new therapeutic approaches. Charakida M; O'Neil F; Masi S; Papageorgiou N; Tousoulis D Curr Pharm Des; 2011 Dec; 17(37):4111-20. PubMed ID: 22204372 [TBL] [Abstract][Full Text] [Related]
29. Toward immunomodulatory and anti-inflammatory properties of statins. Arnaud C; Braunersreuther V; Mach F Trends Cardiovasc Med; 2005 Aug; 15(6):202-6. PubMed ID: 16182129 [TBL] [Abstract][Full Text] [Related]
30. High HDL may not protect the heart. Concentrate on lowering LDL for now, experts advise. Harv Heart Lett; 2012 Sep; 23(1):6. PubMed ID: 23097807 [No Abstract] [Full Text] [Related]
31. Psoriasis: can statins play a dual role? Rajpara AN; Goldner R; Gaspari A Dermatol Online J; 2010 Feb; 16(2):2. PubMed ID: 20178698 [TBL] [Abstract][Full Text] [Related]
32. Anti-inflammatory action of statins and reduction of homocysteinemia by vitamin supplementation: interactions among strategies for cardiovascular prevention. Rubba P Nutr Metab Cardiovasc Dis; 2000 Aug; 10(4):173-6. PubMed ID: 11079254 [No Abstract] [Full Text] [Related]
33. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Patrick L; Uzick M Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071 [TBL] [Abstract][Full Text] [Related]
35. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?]. Pérez A Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585 [No Abstract] [Full Text] [Related]
36. Regarding "Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study". Goldstein MR; Mascitelli L; Pezzetta F J Vasc Surg; 2009 Jun; 49(6):1632-3; author reply 1633. PubMed ID: 19497532 [No Abstract] [Full Text] [Related]
37. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Chow SC Arch Immunol Ther Exp (Warsz); 2009; 57(4):243-51. PubMed ID: 19578811 [TBL] [Abstract][Full Text] [Related]
38. Innate immune molecular connections between atherosclerosis and statins: can the clinical laboratory venture beyond C-reactive protein? Staros EB Am J Clin Pathol; 2006 Jan; 125(1):8-15. PubMed ID: 16482986 [TBL] [Abstract][Full Text] [Related]